Get news updates from AACRMeetingNews.org
Subscribe below to get email updates from AACRMeetingNews.org
AACR Past President David A. Tuveson, MD, PhD, FAACR, organized a symposium at the Annual Meeting that examined potential mechanisms underlying the relationship between stress and cancer, and how premature tissue aging may participate in an intrinsic and/or extrinsic fashion. Read more
Gregory H. Reaman, MD, co-chaired and delivered opening remarks in a session that featured experts in pediatric brain tumors, solid malignancies, and leukemia, who reviewed existing evidence on the contribution of molecular profiling to the clinical care of pediatric cancer patients. Read more
The 11 sessions in the Regulatory Science and Policy Track examined a wide range of regulatory science topics, including issues surrounding methods to determine appropriate dosing for oncology drugs, new approaches to reduce cancer disparities, and ways to use real-world data for regulatory approval, among many other import... Read more
Susan M. Kaech, PhD, chaired an Annual Meeting symposium that explored the intersection of cancer metabolism and immunometabolism. Researchers are gaining a better understanding about the impact of the tumor microenvironment on nutrient availability and the metabolic states of tumor cells and immune cells. Read more
Roel Verhaak, PhD, chaired an Annual Meeting session that explored the fundamental concepts and cutting-edge developments in the understanding of extrachromosomal DNA (ecDNA) amplifications in cancer. The presence of ecDNA is associated with poor patient survival. Read more
The AACR Annual Meeting 2022 program featured 13 forums on topics ranging from trust in science to genome-wide association studies, resistance to immune checkpoint blockade, breaking down silos in clinical trials, and putting precision oncology into clinical practice for pediatric cancer patients. Keep reading for a recap o... Read more
NCI Acting Director Douglas R. Lowy, MD, FAACR, chaired an Annual Meeting symposium that provided an update on clinical vaccine research efforts designed to prevent HPV, pancreatic cancer, and Lynch syndrome. Read more
Beth McCormick, PhD, and two other investigators discussed the complex interplay between microorganisms and the tumor microenvironment and reviewed ongoing research using microbes to promote treatment response during an Annual Meeting symposium. Read more
Craig M. Crews, PhD, was honored for his groundbreaking research that spearheaded new and revolutionary therapeutic approaches, including the development of novel proteasome inhibitors and proteolysis targeting chimera technology. Read more
Neoantigens have emerged as prime targets for cancer immunotherapy in the past decade and researchers continue to explore approaches to improve antigen selection and immunogenicity for vaccine development. Ugur Sahin, MD, and Lélia Delamarre, PhD (left to right), discussed the latest advances at the Annual Meeting. Read more
Klaus Pantel, MD, PhD, Catherine Alix-Panabières, PhD, and Victor E. Velculescu, MD, PhD (left to right), discussed the current state of the art, open questions, and potential clinical applications of liquid biopsy during the AACR Annual Meeting. Read more
Philip E. Castle, PhD, MPH, Ernest T. Hawk, MD, MPH, and Nickolas Papadopoulos, PhD (left to right), discussed the challenges and benefits of detecting precancerous lesions in the era of minimally invasive tests like liquid biopsies on the final day of the Annual Meeting. Read more
Growing evidence suggests a critical role for clonal hematopoiesis (CH) in driving complications associated with oncological care through systemic inflammation. Three investigators, including Ross L. Levine, MD, provided a state-of-the-art update on CH during one of the first-ever AACR Annual Meeting sessions dedicated to t... Read more
During the final session of the AACR Annual Meeting 2022, Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, and three members of the Program Committee reviewed several significant highlights and important themes from the meeting. Read more
On the final day of the Annual Meeting, Anna D. Barker, PhD, chaired a plenary session dedicated to tumor evolution. “We are going to see people putting evolution to work in the very near future,” she said. Read more
“There is no one leader in this overall effort of creating trust in science. The AACR is an engine behind the overall effort, but we must come together from various sectors to develop a common agenda and achieve this goal,” said William S. Dalton, MD, PhD. Read more
The cancer world changed in 1982 when three labs, working independently, identified the first human oncogene, RAS, and cloned three variants: HRAS, KRAS, and MRAS. Patricia M. LoRusso, DO, PhD (hc), chaired a special symposium at the Annual Meeting to mark the anniversary and review more recent advances. Read more
Steven A. Rosenberg, MD, PhD, FAACR, was honored for pioneering the development of effective immunotherapies and gene therapies for patients with advanced cancers, among other significant research contributions. Read more
Although biology plays a role in all types of cancer, a person’s “ZNA,” or the zip code where they live, is just as important to consider as DNA and may play an even greater role in health outcomes, according to Robert A. Winn, MD. Read more
Donna R. Rivera, PharmD, MSc (left), and Deborah Schrag, MD, MPH, moderated an Annual Meeting symposium that featured several case studies illustrating how real-world data can be translated to real-world evidence. Read more
During a plenary session on Tuesday, April 12, four researchers discussed the latest advances in immuno-oncology, including developments in the understanding of immunotherapy modalities, efficacy, and combination strategies. Carl H. June, MD, FAACR, chaired the session. Read more
The Annual Meeting’s final Clinical Trials Plenary Session featured trials of immunotherapy drug combinations that could benefit patients who don’t respond to single-agent immunotherapy or chemotherapy combinations. Timothy A. Yap, MD, PhD, chaired the session. Read more
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Wednesday’s schedule to help plan your day. Read more
Organized by the AACR Chemistry in Cancer Research working group, this year’s three "New Drugs on the Horizon" sessions featured first disclosures of the discovery and structure of 12 novel agents. Read more
“There are some very novel drugs targeting the DNA damage response pathway that are being developed, including some presented for the very first time during this session,” said Julie R. Brahmer, MD, MSc, co-chair of the Annual Meeting Clinical Trials Committee. Read more
National Cancer Institute Principal Deputy Director Douglas R. Lowy, MD, FAACR, visited the AACR Annual Meeting on Monday, April 11. He becomes NCI acting director at the end of April when Norman E. Sharpless, MD, FAACR, steps down as head of the NCI. Read more
Trey Ideker, PhD, led a Monday morning session on interpreting and building trust in artificial intelligence models in cancer research. AI techniques hold promise but still lack interpretability and transferability in translational medicine, he said. Read more
Mariana C. Stern, PhD, led a plenary session featuring cancer researchers from around the world who discussed the integration of complex data and diversity to achieve better health equity. Read more
John Haanen, MD, PhD, was one of four researchers to report positive results from four clinical trials of cellular immunotherapies during the first Clinical Trials Plenary Session at the Annual Meeting. Read more
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Tuesday’s schedule to help plan your day. Read more
Researchers from three projects, including one led by Jian Carrot-Zhang, PhD, described how data from AACR Project GENIE is furthering their research objectives during an Annual Meeting session on Sunday. Read more
Outgoing AACR President David A. Tuveson, MD, PhD, FAACR, discussed the unique challenges in the fight against pancreatic cancer and what it will take to achieve the aggressive targets of the Cancer Moonshot initiative in this patient population. Read more
As more and more cancer therapies are tailored to individual tumors, the search for predictive biomarkers in radiation oncology remains ongoing. Anna Wilkins, PhD, Julie K. Schwarz, MD, PhD, and Sean P. Pitroda, MD (left to right), described their research in this area during a Monday morning symposium. Read more
The final six forums in this year’s program will be held this evening. These 90-minute sessions offer a unique, discussion-based format designed to engage attendees. AACR Meeting News has a preview of all six. Read more
The Opening Plenary Session at the AACR Annual Meeting 2022 featured five state-of-the-art scientific presentations and a special lecture on the future of cancer research by Charles L. Sawyers, MD, FAACR. Read more
Several researchers, including session chair Catriona H. M. Jamieson, MD, PhD, discussed the promise of precancer research on Saturday, April 9, during an Annual Meeting plenary session dedicated to the science of precancer. Read more
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Monday’s schedule to help plan your day. Read more
AACR CEO Margaret Foti, PhD, MD (hc), celebrated the return to an in-person meeting during the Opening Session Sunday morning and applauded President Biden’s renewed commitment to the Cancer Moonshot initiative. Read more
National Cancer Institute Principal Deputy Director Douglas R. Lowy, MD, FAACR, will deliver some of his first public comments since being named incoming acting director of the NCI last week. Read more
AACR President David A. Tuveson, MD, PhD, FAACR, organized and will chair today’s Presidential Select Symposium on aging, stress, and cancer. The symposium is a direct result of Tuveson’s interest in conditions that predispose individuals to develop cancer. Read more
The first seven of 13 forums in this year’s program will be held today. An afternoon session will focus on trust in science, followed by six concurrent sessions this evening. AACR Meeting News has a preview of all seven. Read more
AACR President David A. Tuveson, MD, PhD, FAACR, uses Wayne Gretzky’s predictive approach to playing hockey as an example for how the cancer community could meet President Biden’s goal of reducing cancer mortality by 50 percent in the next 25 years. Read more
Camille C. R. Ragin, PhD, MPH, led a Saturday afternoon Educational Session that examined how implementation science can be leveraged to address problems that have contributed to health inequities in cancer research and care in the U.S. and abroad. Read more
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Sunday’s schedule to help plan your day. Read more
Three researchers, including session chair Kathy McCoy, PhD, discussed the links between dietary modification of the microbiome and response to immunotherapy during a Friday afternoon Educational Session. Read more
Jiaoti Huang, MD, PhD, was one of three pathologists who discussed how advances in technology are improving the accuracy and specificity of tumor assessment during a Saturday morning session. Read more
The quest to overcome drug resistance is inextricably linked to Joseph R. Bertino, MD, FAACR, who helped define the mechanisms of action and resistance to one of the most important cancer chemotherapy agents, methotrexate. Read more
Three experts, including H. Courtney Hodges, PhD, provided an update on emerging concepts and technologies to visualize tumor biology during a Saturday morning Educational Session. Read more
Catriona H. M. Jamieson, MD, PhD, previews the Precancer Discover Science plenary, which examined new perspectives on cancer prevention, an integral part of the AACR’s research and health policy efforts. Read more
The Opening Plenary Session reflects the meeting’s theme by showcasing several examples of how researchers are decoding the complexities of cancer, said Program Committee Chair Marcia R. Cruz-Correa, MD, PhD. Read more
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Saturday’s schedule to help plan your day. Read more
Julie R. Brahmer, MD, MSc, and Timothy A. Yap, MD, PhD, preview the Annual Meeting’s four Clinical Trials Plenary Sessions, which will include important studies looking at cellular therapies, novel immunotherapeutics, and molecularly targeted therapeutics. Read more
Steven A. Rosenberg, MD, PhD, FAACR, is being recognized for pioneering the development of effective immunotherapies and gene therapies for patients with advanced cancers, among other significant research contributions. Read more
The AACR honored dozens of cancer researchers, physician-scientists, advocates, and policymakers for their achievements during the Annual Meeting. Read more
This year’s multidisciplinary program reflects the AACR’s focus on the various facets of cancer etiology, progression, and treatment and the factors that influence each individual patient’s experience, including genetics, environment, and lifestyle factors. Read more
The Annual Meeting program officially launches today and features 50 Educational Sessions and 13 Methods Workshops covering the hottest cancer research topics, according to Lillian L. Siu, MD, Chair of the Annual Meeting Education Committee. Read more
This year’s class of 33 new Fellows joins the 256 distinguished scientists, clinicians, and physician-scientists previously honored with the AACR’s highest level of recognition. Read more
Hunter is being honored for the discovery of protein tyrosine phosphorylation as a common cellular mechanism capable of contributing to cellular growth and proliferation and, in some cases, the development of cancer. Read more
DuBois is being honored for elucidating the role of cyclooxygenase 2 in colon cancer and the contributions of the lipid metabolite prostaglandin E2 to tissue inflammation in the etiology of colon cancer. Read more
Catriona H. M. Jamieson, MD, PhD (left), and Marcia R. Cruz-Correa, MD, PhD (right), preview the Precancer Discovery Science Plenary Session on Saturday, April 9, and the Opening Plenary Session on Sunday, April 10. Read more
In addition to the two weekend plenaries, the Annual Meeting program includes four other plenary sessions covering some of the hottest topics, latest discoveries, and most recent advances in cancer research and treatment. Read more
The AACR NextGen Stars program was created to offer enhanced visibility to early-career scientists. This year’s 14 AACR NextGen Stars will present their research during several major symposia and sessions at the Annual Meeting. Read more
AACR Project GENIE, an international cancer registry assembled through data sharing between 19 of the leading cancer centers in the world, has surpassed its organizers’ greatest expectations, according to Shawn M. Sweeney, PhD. Read more
Since 1961, the AACR has continued to expand its collection of annual awards and lectureships that recognize and honor laboratory researchers, physician-scientists, and population scientists around the world. Read more
The Annual Meeting will serve as a kickoff for a year of events celebrating the milestone. Special attractions in New Orleans include a 115th Anniversary Landmarks exhibit and an anniversary shop with commemorative merchandise. Read more
Louisiana native and two-time Super Bowl champion Brandon Bolden (left) will be joined at the starting line by AACR President David A. Tuveson, MD, PhD, FAACR (right), who plans to compete in the annual fundraising event. Read more
The Annual Meeting Program Committee, Education Committee, and Clinical Trials Committee have developed an exciting program that examines all aspects of cancer development and factors that influence each individual patient’s experience. Read more
The world’s largest meeting dedicated to cancer research hits the road for the first time in two years after the COVID-19 pandemic forced the cancellation of in-person gatherings in 2020 and 2021. Virtual attendance is also an option this year. Read more
Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, previews the Annual Meeting scientific program, which covers the most important advances and hottest topics in cancer research. Read more
Among the themes and topics expected to garner a lot of attention this year are trials looking at cellular therapies, novel immunotherapeutics, and molecularly targeted therapy drugs, according to Timothy A. Yap, MD, PhD, and Julie R. Brahmer, MD, MSc. Read more
Attendees in New Orleans will have access to all meeting events, including several onsite networking events and hubs. Both virtual and in-person attendees will have access to watch/view session recordings on the virtual meeting platform for three months after the meeting. Read more
Vaccination and mask policies are based on guidelines from the U.S. Centers for Disease Control and Prevention and may be updated if CDC recommendations change. Read more